Physician profile
Mark P Priebe
NPI 1831138684
$1,312.51
in general payments reported to CMS, 2019-2025
22 companies · $34.11 in 2025
The $34.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $118 · 2022: $22.81 · 2023: $72.49 · 2024: $17.35 · 2025: $34.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.10 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $184.04 | 2019-2023 | |
| Amgen INC. | $167.38 | 2019-2020 | |
| Glaxosmithkline, LLC. | $152.43 | 2019-2020 | |
| Novo Nordisk INC | $139.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $92.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $84.90 | 2019-2020 | |
| Abbvie INC. | $62.74 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $60.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.43 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $46.34 | 2019-2020 | |
| Astellas Pharma US INC | $39.12 | 2019-2023 | Veozah |
| Merck Sharp & Dohme LLC | $35.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $31.53 | 2019 | |
| Sanofi Pasteur INC. | $27.07 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.37 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $22.81 | 2022 | |
| Amarin Pharma, INC. | $19.84 | 2020 | |
| Genentech USA, INC. | $15.78 | 2019 | |
| Allergan, INC. | $15.54 | 2019 | |
| Exact Sciences Corporation | $15.26 | 2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $14.55 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Priebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.